Abstract
Enzymatic derived oligophenols from apocynin can be effective inhibitors of human vascular NADPH oxidase. An isolated IIIHyQ has been shown to inhibit endothelial NADPH oxidase with an IC50 ~30 nM. In vitro studies demonstrated that IIIHyQ is capable on disrupting the interaction between p47phox and p22phox, thereby blocking the activation of the Nox2 isoform. Herein, we report the role of key cysteine residues in p47phox as targets for the IIIHyQ. Incubation of p47phox with IIIHyQ results in a decrease of ~80% of the protein free cysteine residues; similar results were observed using 1,2- and 1,4-naphthoquinoes, while apocynin was unreactive. Mutants of p47phox, where each Cys was individually replaced by Ala (at residues 111, 196 and 378) and Gly (at residue 98), were generated to evaluate their individual importance in IIIHyQ-mediated inhibition of p47phox interaction with p22phox. Specific Michael addition on Cys196, within the N-SH3 domain, by the IIIHyQ is critical for disrupting the p47phox-p22phox interaction. When a C196A mutation was tested, the IIIHyQ was unable to disrupt the p47phox-p22phox interaction. However, the IIIHyQ was effective at disrupting this interaction with the other mutants, displaying IC50 values (4.9, 21.0, and 2.3 μM for the C111A, C378A, and C98G mutants, respectively) comparable to that of wild type p47phox.
Keywords: Human vascular NADPH oxidase, Enzyme inhibition, Apocynin derived oligophenols, p47phox, p22phox
INTRODUCTION
Reactive oxygen species (ROS) regulate cellular signaling, affecting several aspects of cellular function, such as proliferation, migration, gene expression, and cell death. Several enzymes are expressed in the vasculature and contribute to ROS generation (e.g., endothelial nitric oxide synthases, cytochrome P450s, xanthine oxidase, and NADPH oxidases). Among this group of enzymes, NADPH oxidases catalyze superoxide (O2•−) synthesis that triggers formation of ROS (e.g., hydrogen peroxide and hydroxyl radical), species that play a critical role in the development of oxidative stress-related cardiovascular diseases, including ischemia, restenosis, stroke, and arteriosclerosis [1–4]. At least three isoforms of NADPH oxidase are expressed in vascular endothelial cells (VEC), Nox1, Nox2 and Nox4 [5,6], with Nox2 playing a critical role in ROS generation [7]. For example, Nox2 is upregulated ~8-fold and its production of O2•− increases 2–3 fold under induced oxidative stress [7]. Nox 2 has 100% homology with the NADPH oxidase found in neutrophils, an enzyme involved in pathogen neutralization. Similar to the neutrophil enzyme, Nox2 undergoes a complex assembly of membrane- and cytosol-associated subunits to generate the activated enzyme. As depicted in Fig. 1A, translocation of cytosolic subunits (p47phox, p67phox, p40phox and Rac) occurs through binding to the membrane p22phox and gp91phox subunits [8–11]. Phosphorylation of serine residues in p47phox results in conversion of inactive p47phox into an active form of p47phox and allows interaction of p47phox Src homology 3 (SH3) domain with proline rich regions (PRR) of p22phox (Figure 1B); this interaction is essential for activation of the Nox2 isoform [12,13].
Figure 1.
(A) Active conformation of human vascular NADPH oxidase (Nox2 isoform); Interaction between NADPH oxidase subunits p22phox and p47phox. (B) N-SH3 domain of p47phox interacts with the proline rich region (PRR) of p22phox. (C) Cysteine at the 196 position of p47phox is the only cysteine located within the N-SH3 domain and is considered a critical target for quinones to prevent the interaction with p22phox.
Selective inhibitors for NADPH oxidase have been developed, some of which block the interaction of cytosolic subunits with membrane proteins (e.g., the flavonoid derivative S17834, 6,8-diallyl-5,7-dihydroxy-2-(2-allyl-3-hydroxy-4-methoxyphenyl)-1-H-benzo-[b]-pyran-4-one, and peptides such as the antibiotic PR-39) [14–16]; in vivo studies have shown that this flavonoid derivative reduced aortic superoxide anion levels by 40% and aortic atherosclerotic lesions by 60% in apolipoprotein E-deficient mice [15]. In particular, polyphenols have gained significant attention because of their ability to bind proline rich proteins [17,18]. Apocynin is a well-studied inhibitor of NADPH oxidase. Despite the growing number of studies with this phenolic compound, there remain questions of its precise role in NADPH oxidase inhibition. Some studies have revealed that apocynin is not a direct inhibitor of NADPH oxidase [19, 20], while other studies suggest that apocynin acts as a simple antioxidant [19, 21]. However, metabolism in vivo is expected to convert apocynin into reactive molecules, including oligophenols and their quinone analogs [22]. The latter has been observed in vivo. Thallas-Bonker and coworkers found that apocynin attenuates cytosolic superoxide generation in induced diabetic rats [23]. However, it is possible that the observed effect on diabetic rats was due the conversion of apocynin into active metabolites. Indeed, Johnson et al. [20] and Kanegae et al. [24] found a dimer derived from apocynin to be an effective inhibitor, but its precise mode of action has not been determined, although oxidized oligophenolic compounds have been shown to bind to thiol groups and contribute to NADPH oxidase inhibition [25].
In our previous work, we reported a broad complex mixture of derived oligophenols (up to heptamers) obtained from the peroxidase-catalyzed oxidation of apocynin and consisting of demethylated, hydroxylated, and quinone forms [26]. We isolated and fully characterized a trimer hydroxylated quinone (IIIHyQ), which showed strong inhibitory activity (IC50 = 30 nM) against endothelial cell-based NADPH oxidase. The IIIHyQ was able to disrupt the in vitro interaction between a His-tagged p47phox (His-p47phox) and a PRR peptide biotin-p22phox (IC50 = 1.60 μM) [26]. A linear correlation existed between the inhibitory activity against EC-NADPH oxidase and the ability to disrupt the interaction between biotin-p22phox and His-p47phox, suggesting that apocynin derived oligophenols are capable of preventing p47phox-p22phox interaction in vivo. We now hypothesize that IIIHyQ may bind to critical cysteine residues of p47phox, and in particular Cys196 located in the N-SH3 domain (Figure 1C) via Michel adducts. Indeed, similar adducts are well known to occur between benzoquinone, naphtoquinone, anthraquinone or dopamine quinone with Cys residues in proteins [27,28].
In the current work, we have focused on gaining a more complete understanding of the mechanism of NADPH oxidase inhibited by apocynin-derived IIIHyQ. We evaluated the effect of IIIHyQ on the interaction of biotin-p22phox and His-p47phox. Four p47phox mutants were expressed and purified, each containing a simple Cys replacement, thus sequentially eliminating potential targets for quinone binding. This approach resulted in the identification of Cys196 as a critical target for IIIHyQ leading and potentially preventing p47phox-p22phox interaction. We also evaluated the toxicity of the IIIHyQ compared with apocynin using PC-12 cells. This set of results establishes apocynin derived oligophenols, and particularly metabolism-generated quinones, as candidates for potential therapeutic applications.
MATERIALS AND METHODS
Materials
Apocynin, soybean peroxidase (SBP), solvents, phosphate buffered saline (PBS) tablets, H2O2, thiazolyl blue tetrazolium bromide, Tween 20, 3,3′,5,5′-tetramethyl-benzidine (TMB), sodium caseinate, fetal bovine serum, heparin, and endothelial growth supplement were purchased from Sigma-Aldrich (St. Louis, MO). Endothelial cells, PC-12 cells and F12K medium were purchased from ATCC (Manassas, VA). E. coli BL21 (DE3), E. coli Top 10 competent cells, isopropyl β-D-1-thiogalactopyranoside (IPTG), Lucifer Yellow Iodoacetamide and Ni-affinity column (Probond system) were purchased from Invitrogen (Carlsbad, CA). Primers were obtained from Integrated DNA Technologies (Coralville, IA). Antibodies were purchased from Upstate Biotechnology (Waltham, MA). High-affinity streptavidin-coated-96 well plates were purchased from Pierce. LC-MS analyses were performed on a Shimadzu LCMS-2010A. Samples for LC-MS were separated in an Agilent Zorbax 300SB-C18 column (5 μm, 2.1 × 150 mm). Silica gel 230–400 mesh was purchased from Natland International Corporation (Morrisville, NC). Thin layer chromatography (TLC) plates were purchased from Merck (Whitehouse Station, NJ). Microplate reader analyses were performed in a Perkin-Elmer, HTS 7000, Bio Assay Reader.
Enzymatic production of IIIHyQ from apocynin
IIIHyQ was synthesized via SBP-catalyzed oxidation of apocynin as described previously [26, 29]. Briefly, apocynin (6 mmol) was dissolved in 5 mL of dimethylformamide (DMF) and transferred to 490 mL phosphate buffer (50 mM, pH 7). SBP (5 mL of a 1 mg/mL solution) was added and the reaction was initiated by using a syringe pump to introduce H2O2 (30% w/v) at 0.1 mL/min for 12 min to afford 12 mmol H2O2. Finally, the reaction was stopped after 2 h. Soluble and precipitated phases were separated by centrifugation and ethyl acetate was added to the supernatant to extract organic compounds. The extracted supernatant fraction was dried and stored at −20°C under argon. Dried powder (290 mg) was dissolved in chloroform and loaded onto a silica gel column (15 g) and eluted with a gradient of petroleum ether:ethyl acetate (2:1 to 0:1). Unreacted apocynin was recovered in the early fractions (210 mg, Rf 0.62 with petroleum ether:ethyl acetate, 1:1) and further elution with pure ethyl acetate furnished the IIIHyQ as a white powder (14 mg, Rf 0.34 with petroleum ether:ethyl acetate, 1:1). TLC, NMR and High Resolution Mass Spectrometry (HRMS) analyses were performed as previously reported [26].
Site directed mutagenesis
Four mutants of His-p47phox were obtained by site directed mutagenesis using the original plasmid (pET-28a (+), 5369 bp) used for production of recombinant His-p47phox wild type, C98G C111A, C196A, and C378A. Primer design was performed following the guidelines of the QuickChange® Lightning Site-Directed Mutagenesis Kit from Stratagene (Santa Clara, CA); primers (reverse, R, and forward, F) for each mutant are: C98GF (GGCACACTTACCGAGTACGGCTCCACGCTCATGAGCCTGC), C98GR (GCAGGCTCATGAGCGTGGAGCCGTACTCGGTAAGTGTGCC); C111AF (CACCAAGATCTCCCGAGCTCCCCACCTCCTCGACTT), C111AR (AAGTCGAGGAGGTGGGGAGCTCGGGAGATCTTGGTG); C196AF (GAGCGGTTGGTGGTTCGCTCAGATGAAAGCAAAGC), C196AR (GCTTTGCTTTCATCTGAGCGAACCACCAACCGCTC); C378AF (CCTCATCCTGAACCGCGCTAGCGAGAGCACCAAGC), C378AR (GCTTGGTGCTCTCGCTAGCGCGGTTCAGGATGAGG). The calculated melting temperature for each primer was ≥ 78°C and the cycling parameters used for PCR are described in the instruction manual of the mutagenesis kit from Stratagene. After PCR reactions, DNA was inserted into E. coli Top 10 cells and plasmid purified samples were sent for sequencing (MCLab, San Francisco, CA) to confirm the correct mutations (see Supporting Information for primer design).
Production and purification of His-p47phox and biotin-p22
A proline-rich p22phox peptide N′-151PPSNPPPRPPAEARK165-C′, which was biotinalyted at the N-terminus and amidated at the C-terminus was obtained from Genemed Synthesis Inc. (South San Francisco, CA). A biotin group was attached through a 4-residue spacer consisting of SGSG. The purity of the peptide was 99.99%. Endothelial cell (EC)-derived p47phox (wild type) DNA (6-His tagged) was obtained from U. of Albany and Stratton VA Medical Center and confirmed by DNA sequence analysis (U. of Maine). His-p47phox proteins (wild type and mutants) were expressed in BL21 (DE3) cells for 9 h using (IPTG 0.5 mM) at 35°C. The protein was purified using a Ni-affinity column (ProBond System) and the purity (80%) was calculated with the Image J software (NIH).
Biotin-p22 and His-p47phox interaction
Interaction of His-p47phox (mutants and wild type) with the biotin-p22phox peptide was assessed using ELISA, as previously described [26, 30]. Briefly, experiments were performed in high-affinity streptavidin-coated-96 well plates. To block non-specific binding sites, each well was re-blocked with 300 μL of PBS supplemented with 0.1% (v/v) Tween 20 and 1% sodium caseinate. To each well, 100 μL of biotin-p22phox (2 μM) peptide solution were added and incubated at room temperature for 1 h. After washing each well four-times with 300 μL PBS-Tween 20 solution, 100 μL of 0.30 μM His-p47phox (in PBS-Tween solution containing 1% sodium caseinate) and IIIHyQ (0 – 1000 μM) were added to each well and incubated at room temperature for 1 h. Unbound IIIHyQ was removed by washing four times with 300 μL/well PBS-Tween 20 solution. The amounts of bound His-p47phox were quantified by adding 100 μL/well of polyclonal goat anti-p47phox (diluted 1:2000 in PBS-Tween 20 solution containing 1% sodium caseinate) and incubating at room temperature for 1 h. Each well was washed four times with 300 μL PBS-Tween 20 solution and incubated with 100 μL/well of HRP-conjugated rabbit anti-goat IgG secondary antibody (diluted 1:10000 in PBS-Tween solution containing 1% sodium caseinate) at room temperature for 1 h. The plate was finally washed four times with 300 μL/well of PBS-Tween solution and two additional washes with 300 μL/well of PBS. Detection of peroxidase activity was performed with a ready-to-use TMB liquid substrate by adding 200 μL/well and incubating at room temperature for 30 min. The reaction was stopped with 100 μL/well of 0.5 M H2SO4 solution and the absorbance was read at 450 nm in the microplate reader. All experiments were performed in triplicate and results were quantified from a standard curve of the interaction between biotin-p22phox (2 μM) and His-p47phox (0 to 0.5 μM). As positive controls, similar experiments were carried out using 1,2-naphthoquinone and 1,4-naphthoquinone and phenylarsine oxide (PAO) was used as a negative control.
Quantification of cysteines
Reactivity of cysteines with quinones was determined using the fluorescent dye Lucifer yellow iodoacetamide (following the protocol from Invitrogen). After purification in a Ni-column, wild type His-p47phox buffer was exchanged with 10 mM phosphate buffer (pH 7.0) using an Amicon ultracentrifuge filtration device (5 kDa MWCO). Wild type His-p47phox (50 μM) was then incubated with the IIIHyQ, using 1,2- and 1,4- naphthoquinone as positive controls, and apocynin as negative control (each compound at a final concentration of 500 μM). Lucifer yellow iodoacetamide (10 mM) was added and the reaction allowed proceeding at 4°C overnight in dark. To separate excess dye and protein conjugate, desalting spin columns (Zeba Spin Desalting Columns, 7k MWCO, 0.5 mL) were used three times until complete elimination of background fluorescence. After removal of the dye, protein concentration was determined by bicinchoninic acid (BCA) protein assay. Finally, fluorescence spectra were taken at an excitation wavelength of 426 nm, showing a maximum of emission intensity ~530 nm.
Intracellular production of superoxide via DHE staining
Qualitative determination of intracellular superoxide was performed via dihydroethidium (DHE) fluorescence. DHE permeates endothelial cells, and in the presence of superoxide and other ROS is oxidized to the red fluorescent 2-hydroxyethidium and ethidium, respectively, which are trapped with DNA resulting in bright red fluorescence. Although DHE can react with other ROS [31–33], the following method describes the generation of O2•− after the selective activation of vascular NADPH oxidase, which is the progenitor of other ROS (e.g., hydrogen peroxide and hydroxyl radical). Endothelial cells were incubated overnight in black, clear-bottom 96-well cell binding surface plates in DMEM in the absence of phenol red. DMEM was removed and the cells were washed twice with PBS and then fresh DMEM (90 μL) was added. EC were incubated for 30 min and 37°C with phorbol myristate acetate (PMA, 1 μM) to activate NADPH oxidase. After consecutive washes with PBS and addition of fresh DMEM (90 μL), EC were incubated with 1 mM IIIHyQ, apocynin, and phenylarsine oxide (PAO) [34] for 2 h at 37°C. DMEM was removed and cells washed two times with PBS, and fresh DMEM was then added. Finally, the cells were incubated with DHE (3 μM) for 30 min and then NADPH (100 μM) to generate O2•−; the experiment was performed in the dark. Cell images were captured after 30 min with a Zeiss LSM 510 laser scanning confocal microscope at excitation and emission wavelengths of 520 and 610 nm, respectively.
Superoxide anion radical (O2•−) scavenging capacity assay
The O2•− scavenging capacity of IIIHyQ was measured by competition with a molecular probe, nitroblue tetrazolium (NBT), following synthesis of O2•− by the hypoxanthine-xanthine oxidase (HPX-XOD) system. Briefly, 200 μL of NBT solution (0.34 mM in PBS), 500 μL HPX (2 mM in PBS), and 100 μL of IIIHyQ prepared at the desired concentration (or the solvent only control) were vortex mixed for 5 s. Then, 200 μL of XOD (0.56 U/mL in PBS) were added and vortex mixed for 30 s. Samples were taken every 10 min to measure the absorbance at 560 nm. NBT has a yellow color that upon reduction by O2•− forms the blue formazan.
Cell toxicity assay
Toxicity of IIIHyQ and apocynin were determined by MTT assay using rat adrenal medullar cells (PC12). Cells were cultured in modified DMEM supplemented with 5% fetal bovine serum, 10% horse serum, and 1% penicillin-streptomycin. The cell suspension (110,000 cells/mL) was separated into aliquots of 90 μL in a 96-well microtiter plate (CellBIND, Corning, Lowell, MA) and allowed to adhere for 24 h. Afterward, 10 μL of IIIHyQ and apocynin solutions were added (to cover a range of concentrations from 0 to 1 mM, in 1% DMSO) to the microtiter plate, and the cells were further incubated for 48 h at 37 °C. The medium was then removed, and the cells were washed with PBS. Next, DMEM (200 μL) and thiazolyl blue tetrazolium bromide (50 μL of 2.5 mg/ml) were added to each well for 3 h at 37 °C. Finally, these solutions were removed, 250 μL of DMSO was added, the plate was shaken (~ 75 rpm) for 20 min, and the absorbance was measured at 562 nm. The cytotoxicity values were normalized to the PBS (1% DMSO) control without IIIHyQ and apocynin.
RESULTS AND DISCUSSION
Interaction of the IIIHyQ with p47phox
The mechanism of NADPH oxidase inhibition by apocynin-derived enzymatic oxidation products remains unclear. In phagocytes, myeloperoxidase is expected to convert apocynin into active metabolites [24,35,36]. Along these lines, we generated a library of potential inhibitors NADPH oxidase, resulting in the identification of a IIIHyQ as a strong inhibitor of the human EC-NADPH oxidase via blocking the interaction between p47phox and p22phox subunits. We hypothesize that the IIIHyQ may bind to critical Cys residues on p47phox preventing its translocation to the membrane. p47phox contains four Cys residues at positions 98, 111, 196, and 378. Cys196 is located within the N-SH3 domain, which binds the PRR of p22phox (Figure 1B).
To elucidate the role of specific Cys residues, and particularly the Cys196 of p47phox on interaction with p22phox in the presence of IIIHyQ, four mutants (C98G-p47phox, C111A-p47phox, C196A-p47phox, and C378A-p47phox) of recombinant p47phox were generated. Dose response analysis of IIIHyQ on C98Gp47phox, and C378Ap47phox enzyme-linked immunosorbant assay (Figure 2A) shows that the apocynin-derivative disrupts the interaction with biotin-p22phox giving comparable IC50 values (4.9, and 2.3 μM respectively; Figure 2B, and 2E) to the value previously reported using the wild type p47phox (1.60 μM) [26], while IC50 value using C111Ap47phox (21.0 μM) was an order of magnitude higher (Figure 2C). However, when Cys196 was replaced by Ala, the IIIHyQ was unable to block the interaction over the entire dose range (Figure 2D). This was interesting, as Cys196 is the only cysteine located within the SH3 domain, and particularly within the N-terminal SH3 domain that binds the PRR of p22phox. Cys196, therefore, appears to be a critical target to prevent protein-protein interactions necessary for NADPH oxidase activation. Several quinones (for example 1,2- and 1,4- naphthoquinones) are known to form Michael adducts with cysteines residues [28]. As controls, 1,2-naphthoquinones and 1,4-naphthoquinone were evaluated for their effects on the interaction of His-p47phox with biotin-p22phox. Using wild-type His-p47phox, both quinones were able to prevent this protein-protein association with comparable IC50 values (0.2 and 0.7 μM respectively; Figures 3A and 3B). However, when the mutant C196Ap47phox was used, neither naphthoquinone had any effect (Figures 3C and 3D).
Figure 2.
Interaction between biotin-p22phox and recombinant His-p47phox (wild type and mutants) in presence of IIIHyQ. (A) Scheme of the ELISA, (B) Dose response using C98Gp47phox (● IC50 = 4.9 μM), (C) C111Ap47phox (● IC50 = 21.0 μM), (D) C196Ap47phox (● IC50 = not determined), and (E) C378Ap47phox (● IC50 = 2.3 μM).
Figure 3.
ELISA controls with quinone structures. Effect of 1,2- and 1,4- naphthoquinones on the interaction between biotin-p22phox and recombinant His-p47phox. (A) biotin-p22 phox – wild type His-p47phox interaction with 1,2-naphtoquinone (■ IC50 = 0.2 μM), (B) biotin-p22 phox – wild type His-p47phox interaction with 1,4-naphtoquinone (■ IC50 = 0.7 μM), (C) biotin-p22phox – C196Ap47phox interaction with 1,2-naphtoquinone, and (D) biotin-p22 phox – C196Ap47phox interaction with 1,4-naphtoquinone (IC50 values of C and D were not determined).
The reactivity of the IIIHyQ on p47Phox Cys residues was determined using the fluorescent dye Lucifer Yellow iodoacetamide (Figure 4A). The 1,2- and 1,4-naphthoquinones were used as positive controls, and apocynin was used as a negative control. The fluorescence spectra (Figure 4B) show a significant decrease (~80%) of total Cys-thiol groups after the incubation with the IIIHyQ, as well as the naphthoquinones, while incubation with apocynin did not result in appreciable reduction in the fraction of free Cys residues. This result suggests that IIIHyQ is not selective for Cys196, which is consistent with the results of Park and co-workers using the fluorescent probe N,N′-dimethyl-N-(iodoacetyl)-N′-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) ethyleneamine [37]. The latter and the reduction of ~80% of total cysteines indicate that the IIIHyQ is not specific for Cys196 but its modification seems to be critical to prevent the interaction with p22phox.
Figure 4.
Quantification of cysteines in recombinant His-p47phox incubated with apocynin, IIIHyQ, 1,2-naphtoquinone, and 1,4-naphthoquinone. (A) Chemical representation of the Michael adduct between IIIHyQ and Cys. (B) Fluorescent spectra of Lucifer iodoacetamide complexed with cysteines of wild type p47phox.
Effect of the IIIHyQ on NADPH oxidase following enzyme activation
NADPH oxidase inhibition can be a result of at least two mechanisms. One mechanism involves interference of enzyme activation, e.g., by preventing translocation of cytosolic subunits to the cell membrane. A second mechanism involves the inhibition of the already assembled and activated enzyme. Along these lines, it is important to note that few attempts have been made to evaluate inhibition when the NADPH oxidase is already activated and the target sites for the inhibitors may be restricted. For example, PAO is ineffective as an inhibitor once NADPH oxidase is activated [38]. We proceeded to investigate whether the IIIHyQ was an effective inhibitor following NADPH oxidase activation. To that end, we activated the enzyme within EC with PMA and followed intracellular O2•− formation by DHE, a cell-permeable dye that reacts with O2•− to generate 2-hydroxyethidium [31, 33]. The production of O2•− was then examined upon addition of IIIHyQ. As shown in Figure 5A, the level of O2•− decreased in the presence of IIIHyQ in relation to apocynin and PAO, although the inhibition was not as striking as addition of IIIHyQ prior to NADPH activation. Nevertheless, it is interesting that IIIHyQ can achieve some degree of inhibition once enzyme assembly had occurred. One explanation is that IIIHyQ may be able to bind to Cys196 even after the p47Phox – p21Phox association takes place. If this occurs, then once IIIHyQ binds to Cys196, the two enzyme subunits dissociate, thereby eliminating enzyme activity. Another possibility is that other protein-inhibitor interactions take place. For example, it has been demonstrated that polyphenols have affinity to physically interact with PRR of proteins and induce conformational changes [17,18]. Interactions between N-SH3 domain of p47phox and PRR of p22phox occur through Van der Waals and hydrogen bond interactions [9,39]. Similar interactions may occur with polyphenols that can disrupt the association of p47Phox – p21Phox. Importantly, IIIHyQ does not scavenge. Similar interactions may occur with polyphenols that can disrupt some of those interactions resulting in a reversible effect on NADPH oxidase. As a control, we determined that the IIIHyQ does not scavenge O2•− and the reduction of O2•− levels is due a loss of enzymatic activity (Figure 5B)
Figure 5.
(A) Intracellular O2•− detection by DHE staining in endothelial cells. Inhibitory activity of apocynin, IIIHyQ, and PAO on previously activated NADPH oxidase. (B) O2•− scavenging capacity of IIIHyQ (0–1 mM); ■ IIIHyQ = 0.0 μM, ● IIIHyQ = 0.01 μM, ▲ IIIHyQ = 100.0 μM, ▼ IIIHyQ = 1000.0 μM
Toxicity of apocynin and IIIHyQ
Our results suggest that IIIHyQ does not target a specific cysteine, and thus may be indiscriminately reactive toward other cysteines residues on other proteins within cells, thereby affecting critical pathways that may damage or kill cells. We therefore evaluated the cytotoxicity of IIIHyQ via the standard MTT assay using PC12 cells. As shown in Figure 6, the dose response plots of apocynin and IIIHyQ were similar and only 20% loss in viability occurred at a concentration of 1 mM. This value is far higher that the IC50 values obtained during the NADPH oxidase activity assay (30 nM) and the biotin-p22phox-p47phox (1.60 μM) [26], indicating a potentially wide therapeutic window. These cytotoxicity results are similar to those with the stilbene resveratrol and its peroxidase generated oxidation products [40].
Figure 6.
MTT assay. Cytotoxicity of apocynin and IIIHyQ on PC-12 cells
CONCLUSIONS
We have studied the mechanism of inhibition of the enzymatically derived IIIHyQ from apocynin, with specific attention given to the interaction of p22phox and p47phox. Cysteine residues of p47phox appear to be the primary target for the quinone, with Cys196 in the N-SH3 domain playing a critical role as a site where inhibition. Specifically, the IIIHyQ is ineffective when Cys196 is replaced by alanine. The IIIHyQ also reacts with other Cys residues in p47phox; however, inhibition is eliminated only when a likely Michael addition to the Cys196 occurs. Similar results were obtained with the structurally simpler 1,2- and 1,4-naphthoquinones. Despite the relatively low selectivity of the IIIHyQ on Cys residues, the compound showed minimal cytotoxicity in vitro. Enzymatic oligomerization of apocynin represents an attractive alternative to generate potential inhibitors of NADPH oxidase. Characterization of IIIHyQ and its mechanism of action provide additional insight into the structural features for potent inhibitors of vascular NADPH oxidase, which may prove valuable in the search for effective therapeutic interventions to cardiovascular diseases related to oxidative stress [34].
Highlights.
Inhibition of human vascular NADPH oxidase by a IIIHyQ derived from apocynin
IIIHyQ blocks the p22phox-p47phox interaction preventing the activation of NADPH oxidase
IIIHyQ targets cysteine residues of p47phox as a potential mechanism of inhibition
Cys196 within the N-SH3 domain plays a critical role as a target of the IIIHyQ
Toxicity of the IIIHyQ is low and comparable with the apocynin toxicity
Acknowledgments
This work was supported by NIH (AT002115). We are grateful to Dr. Christopher Bjornsson, Director of Microscopy and Imaging Core Facility (Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute), for his help with confocal fluorescent microscopy analysis.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- 1.Babior BM. NADPH oxidase: An update. Blood. 1999;93:1464–1476. [PubMed] [Google Scholar]
- 2.Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discovery Today. 2006;11:524–533. doi: 10.1016/j.drudis.2006.04.003. [DOI] [PubMed] [Google Scholar]
- 3.Li JM, Mullen AM, Shah AM. Phenotypic properties and characteristics of superoxide production by mouse coronary microvascular endothelial cells. J Mol Cell Cardiol. 2001;33:1119–1131. doi: 10.1006/jmcc.2001.1372. [DOI] [PubMed] [Google Scholar]
- 4.Brandes RP, Kreuzer JR. Vascular NADPH oxidases: Molecular mechanisms of activation. Cardiovasc Res. 2005;65:16–27. doi: 10.1016/j.cardiores.2004.08.007. [DOI] [PubMed] [Google Scholar]
- 5.Kuroda J, Nakagawa K, Yamasaki T, Nakamura K, Takeya R, Kuribayashi F, Imajoh-Ohmi S, Igarashi K, Shibata Y, Sueishi K, Sumimoto H. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells. 2005;10:1139–1151. doi: 10.1111/j.1365-2443.2005.00907.x. [DOI] [PubMed] [Google Scholar]
- 6.Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal. 2006;18:69–82. doi: 10.1016/j.cellsig.2005.03.023. [DOI] [PubMed] [Google Scholar]
- 7.Li JM, Fan LM, George VT, Brooks G. Nox2 regulates endothelial cell cycle arrest and apoptosis via p21 (cip1) and p53. Free Radic Biol Med. 2007;43:976–986. doi: 10.1016/j.freeradbiomed.2007.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ago T, Kuribayashi F, Hiroaki H, Takeya R, Ito T, Kohda D, Sumimoto H. Phosphorylation of p47(phox) directs phox homology domain from SH3 domain toward phosphoinositides, leading to phagocyte NADPH oxidase activation. Proc Natl Acad Sci USA. 2003;100:4474–4479. doi: 10.1073/pnas.0735712100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Groemping Y, Lapouge K, Smerdon SJ, Rittinger K. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell. 2003;113:343–355. doi: 10.1016/s0092-8674(03)00314-3. [DOI] [PubMed] [Google Scholar]
- 10.Li JM, Shah AM. Differential NADPH- versus NADH-dependent superoxide production by phagocyte-type endothelial cell NADPH oxidase. Cardiovasc Res. 2001;52:477–486. doi: 10.1016/s0008-6363(01)00407-2. [DOI] [PubMed] [Google Scholar]
- 11.Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000;87:26–32. doi: 10.1161/01.res.87.1.26. [DOI] [PubMed] [Google Scholar]
- 12.Sumimoto H, Kage Y, Nunoi H, Sasaki H, Nose T, Fukumaki Y, Ohno M, Minakami S, Takeshige K. Role of Src Homology-3 Domains in Assembly and Activation of the Phagocyte NADPH Oxidase. Proc Natl Acad Sci USA. 1994;91:5345–5349. doi: 10.1073/pnas.91.12.5345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res. 2011;34:5–14. doi: 10.1038/hr.2010.201. [DOI] [PubMed] [Google Scholar]
- 14.Selemidis S, Dusting GJ, Peshavariya H, Kemp-Harper BK, Drummond GR. Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc Res. 2007;75:349–358. doi: 10.1016/j.cardiores.2007.03.030. [DOI] [PubMed] [Google Scholar]
- 15.Cayatte AJ, Rupin A, Oliver-Krasinski J, Maitland K, Sansilvestri-Morel P, Boussard MF, Wierzbicki M, Verbeuren TJ, Cohen RA. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets NADPH oxidase. Arterioscl Throm Vasc Biol. 2001;21:1577–1584. doi: 10.1161/hq1001.096723. [DOI] [PubMed] [Google Scholar]
- 16.Shi JS, Ross CR, Leto TL, Blecha F. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47(phox) Proc Natl Acad Sci USA. 1996;93:6014–6018. doi: 10.1073/pnas.93.12.6014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Asquith TN, Uhlig J, Mehansho H, Putman L, Carlson DM, Butler L. Binding of condensed tannins to salivary proline-rich glycoproteins: The role of carbohydrate. J Agr Food Chem. 1987;35:331–334. [Google Scholar]
- 18.Mehansho H, Butler LG, Carlson DM. Dietary Tannins and Salivary Proline-Rich Proteins - Interactions, Induction, and Defense-Mechanisms. Ann Rev Nutr. 1987;7:423–440. doi: 10.1146/annurev.nu.07.070187.002231. [DOI] [PubMed] [Google Scholar]
- 19.Heumuller S, Wind S, Barbosa-Sicard E, Schmidt H, Busse R, Schroder K, Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension. 2008;51:211–217. doi: 10.1161/HYPERTENSIONAHA.107.100214. [DOI] [PubMed] [Google Scholar]
- 20.Johnson DK, Schillinger KJ, Kwait DM, Hughes CV, McNamara EJ, Ishmael F, O’Donnell RW, Chang MM, Hogg MG, Dordick JS, Santhanam L, Ziegler LM, Holland JA. Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium. 2002;9:191–203. doi: 10.1080/10623320213638. [DOI] [PubMed] [Google Scholar]
- 21.Castor LRG, Locatelli KA, Ximenes VF. Pro-oxidant activity of apocynin radical. Free Radic Biol Med. 2010;48:1636–1643. doi: 10.1016/j.freeradbiomed.2010.03.010. [DOI] [PubMed] [Google Scholar]
- 22.Simons JM, Thart BA, Ching T, Vandijk H, Labadie RP. Metabolic-Activation of Natural Phenols into Selective Oxidative Burst Agonists by Activated Human Neutrophils. Free Radic Biol Med. 1990;8:251–258. doi: 10.1016/0891-5849(90)90070-y. [DOI] [PubMed] [Google Scholar]
- 23.Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FYT, Sourris KC, Penfold SA, Bach LA, Cooper ME, Forbes JM. Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product-Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-alpha-Dependent Pathway. Diabetes. 2008;57:460–469. doi: 10.2337/db07-1119. [DOI] [PubMed] [Google Scholar]
- 24.Kanegae MPP, Condino-Neto A, Pedroza LA, de Almeida AC, Rehder J, da Fonseca LM, Ximenes VF. Diapocynin versus apocynin as pretranscriptional inhibitors of NADPH oxidase and cytokine production by peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010;393:551–554. doi: 10.1016/j.bbrc.2010.02.073. [DOI] [PubMed] [Google Scholar]
- 25.Kanegae MPP, da Fonseca LM, Brunetti IL, Silva SO, Ximenes VF. The reactivity of ortho-methoxy-substituted catechol radicals with sulfhydryl groups: Contribution for the comprehension of the mechanism of inhibition of NADPH oxidase by apocynin. Biochem Pharmacol. 2007;74:457–464. doi: 10.1016/j.bcp.2007.05.004. [DOI] [PubMed] [Google Scholar]
- 26.Mora-Pale M, Weiwer M, Yu J, Linhardt RJ, Dordick JS. Inhibition of human vascular NADPH oxidase by apocynin derived oligophenols. Bioorg Med Chem. 2009;17:5146–5152. doi: 10.1016/j.bmc.2009.05.061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Valente C, Moreira R, Guedes RC, Iley J, Jaffar M, Douglas KT. The 1,4-naphthoquinone scaffold in the design of cysteine protease inhibitors. Bioorg Med Chem. 2007;15:5340–5350. doi: 10.1016/j.bmc.2007.04.068. [DOI] [PubMed] [Google Scholar]
- 28.Briggs MK, Desavis E, Mazzer PA, Sunoj RB, Hatcher SA, Hadad CM, Hatcher PG. A new approach to evaluating the extent of Michael adduct formation to PAH quinones: Tetramethylammonium hydroxide (TMAH) thermochemolysis with GC/MS. Chem Res Toxicol. 2003;16:1484–1492. doi: 10.1021/tx0341512. [DOI] [PubMed] [Google Scholar]
- 29.Antoniotti S, Santhanam L, Ahuja D, Hogg MG, Dordick JS. Structural diversity of peroxidase-catalyzed oxidation products of o-methoxyphenois. Org Lett. 2004;6:1975–1978. doi: 10.1021/ol049448l. [DOI] [PubMed] [Google Scholar]
- 30.Dahan I, Issaeva I, Gorzalczany Y, Sigal N, Hirshberg M, Pick E. Mapping of functional domains in the p22(phox) subunit of flavocytochrome b(559) participating in the assembly of the NADPH oxidase complex by “peptide walking”. J Biol Chem. 2002;277:8421–8432. doi: 10.1074/jbc.M109778200. [DOI] [PubMed] [Google Scholar]
- 31.Wind S, Beuerlein K, Armitage ME, Taye A, Kumar AHS, Janowitz D, Neff C, Shah AM, Wingler K, Schmidt HHHW. Oxidative Stress and Endothelial Dysfunction in Aortas of Aged Spontaneously Hypertensive Rats by NOX1/2 Is Reversed by NADPH Oxidase Inhibition. Hypertension. 2010;56:490–497. doi: 10.1161/HYPERTENSIONAHA.109.149187. [DOI] [PubMed] [Google Scholar]
- 32.Zhao H, Kalivendi S, Zhang H, Joseph J, Nithipatikom K, Vásquez-Vivar J, Kalyanaraman B. Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med. 2003;34:1359–1368. doi: 10.1016/s0891-5849(03)00142-4. [DOI] [PubMed] [Google Scholar]
- 33.Zielonka J, Vasquez-Vivar J, Kalyanaraman B. Detection of 2-hydroxyethidium in cellular systems: a unique marker product of superoxide and hydroethidine. Nat Protoc. 2008;3:8–21. doi: 10.1038/nprot.2007.473. [DOI] [PubMed] [Google Scholar]
- 34.Doussiere J, Poinas A, Blais C, Vignais PV. Phenylarsine oxide as an inhibitor of the activation of the neutrophil NADPH oxidase - Identification of the beta subunit of the flavocytochrome b component of the NADPH oxidase as a target site for phenylarsine oxide by photoaffinity labeling and photoinactivation. Eur J Biochem. 1998;251:649–658. doi: 10.1046/j.1432-1327.1998.2510649.x. [DOI] [PubMed] [Google Scholar]
- 35.Lu XY, Wan SN, Jiang J, Jiang XJ, Yang WJ, Yu P, Xu LP, Zhang ZJ, Zhang GX, Shan LC, Wang YQ. Synthesis and biological evaluations of novel apocynin analogues. Eur J Med Chem. 2011;46:2691–2698. doi: 10.1016/j.ejmech.2011.03.056. [DOI] [PubMed] [Google Scholar]
- 36.Ximenes VF, Kanegae MPP, Rissato SR, Galhiane MS. The oxidation of apocynin catalyzed by myeloperoxidase: Proposal for NADPH oxidase inhibition. Arch Biochem Biophys. 2007;457:134–141. doi: 10.1016/j.abb.2006.11.010. [DOI] [PubMed] [Google Scholar]
- 37.Park HS, Park JW. Fluorescent labeling of the leukocyte NADPH oxidase subunit p47phox: Evidence for amphiphile-induced conformational changes. Arch Biochem Biophys. 1998;360:165–172. doi: 10.1006/abbi.1998.0938. [DOI] [PubMed] [Google Scholar]
- 38.Cabec VRL, Maridonneau-Parini I. Complete and reversible inhibition of NADPH oxidase in human neutrophils by phenylarsine oxide at a step distal to membrane translocation of the enzyme subunits. J Biol Chem. 1995;270:2067–2073. doi: 10.1074/jbc.270.5.2067. [DOI] [PubMed] [Google Scholar]
- 39.Ogura K, Nobuhisa I, Yuzawa S, Takeya R, Torikai S, Saikawa K, Sumimoto H, Inagaki F. NMR solution structure of the tandem Src homology 3 domains of p47(phox) complexed with a p22(phox)-derived proline-rich peptide. J Biol Chem. 2006;281:3660–3668. doi: 10.1074/jbc.M505193200. [DOI] [PubMed] [Google Scholar]
- 40.Ladiwala ARA, Mora-Pale M, Lin JC, Bale SS, Fishman ZS, Dordick JS, Tessier PM. Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β. ChemBioChem. 2011;12:1749–1758. doi: 10.1002/cbic.201100123. [DOI] [PMC free article] [PubMed] [Google Scholar]






